In recent weeks, Foundation Medicine announced it expanded its collaboration with Bristol Myers Squibb to develop ...

Bristol-Myers Squibb (NYSE:BMY) expanded its collaboration with Foundation Medicine to develop a next-generation sequencing ...

The Emirates Drug Establishment (EDE) has announced the country’s first fully AI-discovered and developed drug candidate by a ...

UAE unveils ISM0387, its first fully AI-discovered cancer drug candidate, promising targeted treatment for aggressive brain ...

The Emirates Drug Establishment (EDE) has announced the country’s first fully AI-discovered and developed drug candidate by a ...

Roche’s Foundation Medicine is deepening its longstanding ties with Bristol Myers Squibb as the companies team up on a new ...

Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne(R) CDx as a ...

Erasca Inc. (NASDAQ:ERAS) is one of the 11 Stocks With 3x-5x Returns This Year. Erasca has seen its share prices soar by 390 ...

IDEAYA Biosciences, Inc., a leading precision medicine oncology company, announced that the first patient has been enrolled in its phase 1 clinical trial evaluating IDE892, an investigational ...

Investing.com - Truist Securities reiterated a Buy rating and $60.00 price target on Ideaya Biosciences (NASDAQ:IDYA) following the company’s enrollment of the first patient into a Phase I study of ...

SOUTH SAN FRANCISCO - Ideaya Biosciences (NASDAQ:IDYA) enrolled the first patient in its Phase 1 clinical trial of IDE892, an investigational MTA-cooperative PRMT5 inhibitor for MTAP-deleted solid ...

Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in MTAP-deleted cell lines IDE892 is being ...